D-Dimer Levels Predict DVT in Cervical Spinal Cord Injury

This article originally appeared here.
Share this content:
D-Dimer Levels Predict DVT in Cervical Spinal Cord Injury
D-Dimer Levels Predict DVT in Cervical Spinal Cord Injury

TUESDAY, Nov. 10, 2015 (HealthDay News) -- For patients with acute traumatic cervical spinal cord injury (SCI), D-dimer levels can predict the likelihood of developing deep vein thrombosis (DVT), according to a study published in the Nov. 1 issue of The Spine Journal.

Muneaki Masuda, M.D., from the Japan Labour Health and Welfare Organization Spinal Injuries Center in Iizuka, and colleagues conducted a prospective clinical study to define the epidemiology and incidence of DVT in acute traumatic cervical SCI in a Japanese population. A total of 268 patients with acute traumatic cervical SCI were enrolled; 211 patients remained after excluding early drop-out patients. Neurologic status assessment and blood chemistry were performed every week until one month after injury.

The researchers identified DVT in 10.4 percent of patients. All patients who were positive for DVT had severe paralysis classified as C or greater on the American Spinal Injury Association Impairment Scale. Of the clinical and laboratory parameters, only the D-dimer level at two weeks after injury could accurately predict DVT formation, with 16 µg/dL as the optimal threshold of D-dimer for prediction. For detecting DVT, the sensitivity and specificity were 77.3 and 69.2 percent, respectively.

"D-dimer levels may be used to predict the likelihood of DVT development in patients with acute cervical SCI," the authors write. "Such a screening test would be cost-efficient and simple to administer and could then be followed with additional investigations, such as ultrasonography or venography."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »